General Information
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. Abemaciclib is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
About the API
Systematic name
N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazol-6-yl]pyrimidin-2-amine
Trade name(s)
Verzenio
Technology
Synthetic
Molecular Weight
506.59 g/mol
Physical properties
Small Molecule
Therapeutic category
Oncology
Available formulations
Oral Solid